Empowering cross-functional decision makers
Whether guiding research paths, recommending modalities, or prioritizing targets and drug candidates for investment, leaders of drug discovery teams know their decisions have long-lasting impacts. CAS BioFinder helps these leaders and the teams they rely on to advance data-backed recommendations confidently.
Key decisions require input from the entire team
Some decisions in the drug discovery process require input from cross-disciplinary team members, all working together from different perspectives. These decisions can occur at various stages of the drug discovery pipeline, but the goals remain consistent: reducing portfolio risk, aligning cross-team efforts, and prioritizing the pipeline.
How can we confidently select the best modality for our disease-target combination?
CAS BioFinder streamlines modality selection for complex disease-target combinations. Skip over weeks of debate and misalignment with unified target accessibility, pathway context, structural data, and ligand selectivity data. CAS BioFinder integrates this information into analytical models and AI-driven predictions to help teams align biology and chemistry fast.
How can we explore the untapped therapeutic potential of an approved drug?
Unlock new therapeutic opportunities with CAS BioFinder’s drug repurposing intelligence. Instead of piecing together scattered data, CAS BioFinder connects targets, indications, clinical trials, and assay details with predictive bioactivity insights to reveal high-confidence repurposing paths. Turn promising ideas into actionable evidence with confidence.
How can we stay aware of competitive challenges?
Stop piecing together information about active trials, publications, or patents. CAS BioFinder provides clinical trial monitoring with phase and sponsor filters, as well as linked patents and publications, to help teams avoid duplication and IP conflicts.
Ready to start a free trial for your cross-functional drug discovery team?
